Ablation Devices Market to Surpass US$ xxx Million by 2027 - Coherent Market Insights

Global Ablation Devices Market, by Technology Type (Radiofrequency Ablation, Microwave Ablation, Cryoablation, High-Intensity Focused Ultrasound, Laser Interstitial Thermal Ablation, and Others), by Application (Cancer, Ophthalmology, Urology, Gynaecology,  Cardiovascular, and Orthopedic), by Function (Automatic and Robotic), by Procedure (Tumor Ablation, Varicose Veins, Atrial Fibrillation, Aesthetics- Skin Rejuvenation and Tightening, Laser and Other Energy Based Therapies), by End User (Hospitals, Ambulatory Surgical Centers, and Specialty), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$  4,290.82 million in 2019 and is expected to exhibit a CAGR of 10.9% over the forecast period (2019-2027).

Increasing acquisitions, mergers and collaborations by key players is expected to drive the global ablation devices market growth during the forecast period. For instance in 2016, Boston Scientific Corporation, acquired Cosman Medical, Inc., a manufacturer of radiofrequency ablation (RFA) systems. This acquisition has further expanded Boston Scientific’s Spinal Cord Stimulator and Deep Brain Stimulation Systems portfolio. Furthermore, in 2015, EDAP TMS announced a multinational strategic OEM partnership with Quanta System, a leading manufacturer of medical lasers for surgical applications. Through this partnership, Quanta manufactures customized urological stone lasers to be sold under the EDAP brand. Additionally, in 2013, Abbott Laboratories acquired IDEV Technologies, a privately-owned company focused on developing next-generation medical devices for use of ablation catheters in electrophysiology. The company also acquired two other catheter-based medical device companies, namely Advanced Cardiac Therapeutics, Inc. and Topera, Inc., in order to enter the electrophysiology ablation devices market.

Browse 52 Market Data Tables and 48 Figures spread through 305 Pages and in-depth TOC on "Global Ablation Devices Market, by Technology Type (Radiofrequency Ablation, Microwave Ablation, Cryoablation, High-Intensity Focused Ultrasound, Laser Interstitial Thermal Ablation, and Others), by Application (Cancer, Ophthalmology, Urology, Gynaecology,  Cardiovascular, and Orthopedic), by Function (Automatic and Robotic), by Procedure (Tumor Ablation, Varicose Veins, Atrial Fibrillation, Aesthetics- Skin Rejuvenation and Tightening, Laser and Other Energy Based Therapies), by End User (Hospitals, Ambulatory Surgical Centers, and Specialty), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2027"

To know the latest trends and insights related to global Ablation Devices market, click the link below:

https://www.coherentmarketinsights.com/market-insight/ablation-devices-market-464 T

he global ablation devices market is expected to witness significant growth over the forecast period, owing to increasing regulatory approval for ablation Devices, For instance, in April 2019, Innoblative Designs, Inc., received U.S. Food and Drug Administration (FDA) clearance for its SIRA RFA Electrosurgical Device, a novel radiofrequency ablation (RFA) applicator for electrosurgery.

Key Takeaways of the Global Ablation Devices Market:

• The global ablation devices market expected to exhibit a CAGR of 10.9% over the forecast period (2019–2027), owing to increasing acquisition, merger and collaboration activities by key player.
• Among technology type, the radiofrequency ablation segment is expected to account for a major revenue share by 2027, owing to increasing launches of radiofrequency ablation systems. For instance, in February 2019, Medtronic Plc. Launched Accurian Radiofrequency ablation system in the U.S. for nerve tissue ablation and also received 510(k) clearance from the US Food and Drug Administration (FDA).
• Major players operating in the global ablation devices market include Arthrex, Boston Scientific Corporation, Medtronic Plc, Intuitive Surgical, Inc., Johnson & Johnson, Inc., Halyard Health, Abbott Laboratories, EDAP TMS S.A., AtriCure, Inc., and Smith & Nephew.